ONCrg Pipeline Strategies – Oncology Resource Group

Build + Elevate = Best-In-Class

Because each ONCrg Pipeline Strategies cancer area report is carefully built, product by product, trial by trial, by a dedicated CI expert in an exhaustive analysis of scientific, clinical and commercial factors, we elevate your vantage point over the treatment landscape for an unparalleled view of competition and opportunities in your drug market of interest.

Our Presentation and Compendium reports are considered best-in-class, not only because they contain a wealth of practical insight but also because they are updated quarterly with new data from conferences, our sentinel surveillance, and other sources.

ONCrg Pipeline Strategies™LandscapesProfilesCompendiumUpdates

ONCrg Pipeline Strategies

reports provide comprehensive, cancer specific analyses of treatment landscapes for drugs in Ph I/II development and beyond. These resources include a presentation style PPT deck and a detailed PDF compendium which are refreshed quarterly to retain their accuracy and relevance.

Treatment Landscapes:

Each cancer area is described by the framework that best fits the specific cancer market, whether that is by patient subtype, molecular biomarkers, treatment stage and drug class and include visual analytics such as treatment algorithms, benchmarks, registrational trials, and key clinical criteria and guidelines to provide a big picture orientation of how new products may fit into the market landscape.

Product Profiles:

In each cancer area, products in Ph I/II development and beyond are evaluated by class and subclass, and summary slides are provided for each agent including clinical status by region, commercial rights, MOA/ROA, likely scenarios of use (patient subsets), SWOT analysis, milestones (upcoming and last) and clinical trial timelines.

Compendiums:

These cancer area reports take Product Profiles one step further by providing a comprehensive analysis and history of a drug's development and the details of clinical trials completed and in progress, including trial results when available.

Updates:

On a quarterly basis, ONCrg Pipeline Strategies reports are updated with relevant scientific, clinical and commercial developments. ONCrg disease area experts vigilantly monitor multiple secondary and primary sources including peer-reviewed literature, conference news, SEC filings, press releases, and electronic databases such as Adis R&D Insight, ClinicalTrials.gov.

Click your area of interest for a Sample of our Pipeline Strategies report

Solid Tumors
GI - Gastrointestinal	GU - Genitourinary	Women’s Cancer	Lung	Other
Colorectal	Bladder	Breast	NSCLC	Gliomas
Esophageal	Prostate	Endometrial	SCLC	H&N
Gastric	RCC	Ovarian		Melanoma
HCC				STS
Pancreatic

Immuno-Oncology	MOAs	Hematologic Malignancies
IO Emerging	Cell Therapies	ALL	MDS	MPNs
IO Late Stage		AML	MM	NHL
		CLL

Why We Make a Difference

Oncology Coverage

“My team here loves the work ONCrg does – we are constantly pulling these reports up for various reasons and they are so AWESOME! Thanks so much!”

“Wow, very helpful and nice. I appreciate the preview of coming attractions! Thank you very much, helps my story a lot with this unbiased view of the market…”

“I have to say, this is one of the best intelligence services I have ever used. You and your team do a great job”

“What I value most from ONCrg is the unfiltered unbiased view you give irrespective of what manufacturers say. We love the key implications you put together and why they matter”

“As always you guys hit these reports out of the park!! These are so great…. for the first time I’m not making data slides post conferences so thank you for that!”

“ I really liked your past, present and future perspectives. This is some of the best work I have ever seen from a vendor.”

“BRAVO!! Most comprehensive map that I have reviewed for current SOC; and then every MoA and compound in development. Very Impressive. My hat is tipped to your team. I will distribute it across to my team and School is in Session.”

“Our organization is extremely frugal so we always have budget challenges but your value us extremely good and we love working with you so we absolutely want to continue investing in ONCrg.”

“These reports are incredibly informative and helpful as we think about our research strategy and drug developments options in these indications. I greatly appreciate you and the ONCrg team’s efforts to generate these reports and summaries.

“This is great! Until you’ve tried to attend a conference and make sense of what you saw and heard there, you can’t appreciate how hard it is to do it, so this is a really nice way of distilling the information.”

“I have been supporting myeloma brand for 3 years. This level of quality is what I am personally looking for and beyond what typical CI vendors can do….I see you have subject matter experts in each therapeutic area.”

“ONCrg has really good data and really good analysts, which was not what I found at Big Pharma or Small Pharma”

“I really appreciate working with you and the great support you have provided over the last couple of years! The internal feedback was quite positive: Very clear and precise statements; nice format – holistic and comprehensive”

“This is an outstanding summary of ASCO GU! We really appreciate all the detailed summaries and implications provided in this report. The clear insights your team provide continue to be fantastic! We use your upfront slides to convey complicated information to senior leadership.”

“Wow! This is amazing. Literally exactly what I was looking for. Thanks so much!! You’re the best.”

“This fully answers my question. This additional information and timely response is also extremely helpful in filling some of the gaps I had as I prepare for upcoming governance meetings.”

“My organization relies so heavily on ONCrg. I’m one of the strongest advocates and will continue to be, not just for conferences but across the board. “Our senior managers absolutely love the competitive landscape diagrams in your Pipeline Strategies reports.”

“I love the tumor specific reports that give me a lay of the land, are easily digestible. I really appreciate the implications and commentary in each report.”

“I know that many really like what you’re doing…everyone was thankful and found the reports very helpful”

I have always found the ONCrg reports to be valuable and to have evolved in sync with the changing times in oncology (not all vendors have).”

“The fact that ONCrg got our vaccine right is proof that we have done our research”. Also, there were 3 things I picked up from your vaccine presentation that I didn’t know. Quite helpful.”

“The way you do implications was exactly how I would like them to be delivered from a company covering them at ESMO”

“Thank you so much for the Onc-rg reports that your team provides. These reports are very helpful to the field medical team!”

“Thanks team, this is making my life easier already”

“I am quite impressed with the approach that you have taken to developing market assessments based on clinical trials reporting in a variety of settings. I appreciate the access to the meeting trials compendia in my core areas of interest”

“Thank you for the excellent work that you have delivered and for the wonderful partnership we have enjoyed.”

“I find the depth of information and their very succinct explanations to be extremely well written and easy to read, so this would enable me to stay aware of compounds moving up the ladder. Great work”

“I assume you have many clients, so I really appreciate how you can customize the coverage to our needs, I don’t know how you do it.”

“Take the opportunity to check out the “Implications” box on each slide. This agency is excellent at providing valuable context for new data. We will get these reports once a month as well as some really helpful supplementary reports.”

“Thanks for the support and fantastic customer service.”

“Thanks for all the ASCO updates in RCC, breast, IO, etc. They really are terrific and help tremendously with our MA debrief…”

Why We Make a Difference

Oncology Coverage

Footer